0001179110-20-009901.txt : 20200921 0001179110-20-009901.hdr.sgml : 20200921 20200921162219 ACCESSION NUMBER: 0001179110-20-009901 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200917 FILED AS OF DATE: 20200921 DATE AS OF CHANGE: 20200921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boral Anthony L. CENTRAL INDEX KEY: 0001638468 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 201186513 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORP. STREET 2: 215 FIRST STREET, SUITE 340/350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2020-09-17 0 0001597264 Blueprint Medicines Corp BPMC 0001638468 Boral Anthony L. C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Medical Officer Common Stock 2020-09-17 4 M 0 9879 15.01 A 28843 D Common Stock 2020-09-17 4 M 0 3030 8.8 A 31873 D Common Stock 2020-09-17 4 M 0 10227 8.8 A 42100 D Common Stock 2020-09-17 4 S 0 23136 80.00 D 18964 D Stock Option (Right to Buy) 15.01 2020-09-17 4 M 0 9879 0 D 2026-02-03 Common Stock 9879 24347 D Stock Option (Right to Buy) 8.80 2020-09-17 4 M 0 3030 0 D 2025-02-10 Common Stock 3030 0 D Stock Option (Right to Buy) 8.80 2020-09-17 4 M 0 10227 0 D 2025-02-10 Common Stock 10227 0 D Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.05 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option was granted on February 3, 2016. This option is fully vested as of the date hereof. This option was granted on February 10, 2015. This option is fully vested as of the date hereof. /s/ Christopher Frankenfield, Attorney-in-Fact 2020-09-21